Cargando…

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease

BACKGROUND: Although immune checkpoint inhibitors (ICIs) are effective for advanced non-small cell lung cancer (NSCLC), ICIs may cause interstitial lung disease (ILD), which results in treatment discontinuation and is sometimes fatal. Despite the high incidence of ICI-related ILD, there are few canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yusuke, Watanabe, Satoshi, Ota, Takeshi, Kushiro, Kohei, Fujisaki, Toshiya, Takahashi, Miho, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Hokari, Satoshi, Kondo, Rie, Hayashi, Masachika, Ishikawa, Hiroyuki, Miyabayashi, Takao, Abe, Tetsuya, Miura, Satoru, Tanaka, Hiroshi, Okajima, Masaaki, Terada, Masaki, Ishida, Takashi, Iwashima, Akira, Sato, Kazuhiro, Yoshizawa, Hirohisa, Aoki, Nobumasa, Ohshima, Yasuyoshi, Koya, Toshiyuki, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350095/
https://www.ncbi.nlm.nih.gov/pubmed/34430353
http://dx.doi.org/10.21037/tlcr-21-198